Lantern Pharma Inc (LTRN)
6.13
-0.01
(-0.16%)
USD |
NASDAQ |
May 17, 16:00
6.00
-0.13
(-2.12%)
After-Hours: 20:00
Lantern Pharma Cash from Investing (TTM): -0.5255M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -0.5255M |
December 31, 2023 | -0.9302M |
September 30, 2023 | -0.5835M |
June 30, 2023 | -0.8896M |
March 31, 2023 | -0.9581M |
December 31, 2022 | 0.1793M |
September 30, 2022 | -0.6576M |
Date | Value |
---|---|
June 30, 2022 | -1.586M |
March 31, 2022 | -19.35M |
December 31, 2021 | -19.53M |
September 30, 2021 | -19.30M |
June 30, 2021 | -18.30M |
March 31, 2021 | -0.0161M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-19.53M
Minimum
Dec 2021
0.1793M
Maximum
Dec 2022
-6.343M
Average
-0.9302M
Median
Dec 2023
Cash from Investing (TTM) Benchmarks
Eyenovia Inc | -3.970M |
Cassava Sciences Inc | -0.057M |
Alpine Immune Sciences Inc | -86.47M |
Clearside Biomedical Inc | -1.719M |
Poseida Therapeutics Inc | 67.55M |